App combining genomics, fitness and diet highlights nutrigenomics trend
Genetic testing businesses to personalize fitness and diet regimens are making their way into the consumer space, for better or for worse.
These are the key players in the home health testing market
The report lists obvious choices like Quest Diagnostics, LabCorp and 23andMe - and deigns to include even Theranos, despite its recent spate of bad PR.
presented by
The Top-Rated Orthopedic Surgery Centers in the Houston Area and Beyond
Discover Houston's best orthopedic surgery centers and what features — from personalized treatment plans to rehabilitation services — make these top providers stand out in their industry.
The competition: Who is Illumina’s new $100M startup, Grail, up against in cancer liquid biopsy screening?
Who are some other players in the cancer liquid biopsy market? We've got Trovagene, Circulogene, Pathway Genomics and more... but can they compete with Illumina's new startup, Grail?
Pathway Genomics latest app combines cognitive computing, genetics and personal wellness
In an example of the kind of messages users would get, the app may direct them to avoid certain foods based on their metabolism.
Pathway Genomics pays more than $4M to settle kickback allegations from DOJ
"While genomic testing is a valuable and relatively recent medical tool, when specialized laboratories pay for referrals they aren't breaking any new ground but rather engaging in the same old kickback schemes," Special Agent Chris Schrankof said in a statement.
Circulogene launches new liquid biopsy test for cancer
Alabama startup CirculoGene Theranostics has released a new liquid biopsy test for cancer monitoring - but will it stick?
presented by
The Top Surgical Instruments Needed for Extractions
Discover what tools are essential for efficient, safe surgical extractions in today’s health care landscape, from elevators to forceps and beyond.
Other diagnostic companies utilize regulatory loopholes, not just Theranos
Several diagnostic companies use the "laboratory developed test" loophole to avoid regulation and market tests without FDA approval, for better or worse.
Pathway Genomics responds to FDA’s concerns on liquid biopsy test
Pathway Genomics has responded to FDA's warning letter that its liquid biopsy test isn't sufficiently validated clinically, and has an inappropriate marketing model.
Pathway Genomics gets FDA warning letter for its liquid biopsy test
The FDA just sent Pathway Genomics a warning letter for its new liquid biopsy test, calling it "a high risk test that has not received adequate clinical validation and may harm the public health."
Pathway Genomics launches first liquid biopsy test for cancer
Pathway Genomics just launched a liquid biopsy test for multiple cancers, meant for disease monitoring or screening in high-risk patients. It has important implications in precision medicine.
presented by
The Top 6 Best Analytics Tools for Health Care Revenue in 2025
Finding the best analytics tools for health care revenue management can revolutionize operational processes. Compare the leading software options to discover helpful team resources.
From a heart patient’s use of the Apple Watch to Pathway Genomics’ app: 5 must-read stories from MedCity News this week
Here's a look at some of the most popular stories from this past week in healthcare.
Pathway Genomics unveils app to order genetic test to determine optimum fitness, diet regimen
The Pathway Fit app analyzes more than 75 genetic markers known to impact metabolism, exercise, and energy consumption within our bodies.
Study: Customers of commercial genomic testing services understand results more than expected
For average people without a science or healthcare background, genetic testing results would seemingly be difficult to understand, but that might not be the case.
Morning Read: Signs of life in the biotech exit market?
Highlights of the important and the interesting from the world of healthcare: Signs of life in the biotech exit market? Well, maybe. Fourteen venture-backed companies have filed IPOs this year, compared with eight all of last year and seven in 2008. Three of those have been biotechs–Aveo, Alimera and Ironwood. Still, that’s not enough to […]